Serum miR-222-3p as a Double-Edged Sword in Predicting Efficacy and Trastuzumab-Induced Cardiotoxicity for HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Target Therapy

Background: We aimed to explore whether the expression of serum miR-222-3p might contribute to early prediction of therapeutic response, clinical outcomes, and adverse events for HER2-positive breast cancer patients receiving neoadjuvant therapy (NAT). Methods: A total of 65 HER2-positive breast can...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Shan, Wang, Yaohui, Wang, Yan, Peng, Jing, Yuan, Chenwei, Zhou, Liheng, Xu, Shuguang, Lin, Yanping, Du, Yueyao, Yang, Fan, Zhang, Jie, Dai, Huijuan, Yin, Wenjin, Lu, Jinsong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212359/
https://www.ncbi.nlm.nih.gov/pubmed/32426280
http://dx.doi.org/10.3389/fonc.2020.00631

Ejemplares similares

Ejemplares similares